Bovinized crispr / bocas9 gene editing system, method and use
By optimizing the bovine cell codons of the Cas9 protein derived from Streptococcus pyogenes, a bovine CRISPR/boCas9 gene editing system was established, solving the problem of low Cas9 protein cleavage efficiency in bovine cells and achieving highly efficient gene editing, thus providing technical support for transgenic breeding.
Patent Information
- Application Number
- PCT/CN2024/073497
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-01-22
- Publication Date
- 2024-11-14
AI Technical Summary
Existing CRISPR/Cas9 gene editing systems suffer from poor codon bias in bovine cells, resulting in low gene editing efficiency of the Cas9 protein and an inability to efficiently cut target genes.
By optimizing the bovine cell codon preference of the Cas9 protein derived from Streptococcus pyogenes, a bovine CRISPR/boCas9 gene editing system was established. This included optimizing the nucleotide sequences of the boCas9 protein and sgRNA, constructing an expression vector and transfecting it into bovine cells, and detecting the cleavage efficiency using the T7E1 restriction enzyme method.
It improves the cutting efficiency of the bovine CRISPR/boCas9 gene editing system by at least 6 times compared to the CRISPR/Cas9 gene editing system, providing a highly efficient technique for site-specific genome excision, insertion, and modification, and offering an effective tool for transgenic breeding research.
Smart Images

Figure CN2024073497_14112024_PF_FP_ABST
Abstract
Description
Bovine CRISPR / boCas9 gene editing system, method and application Technical Field
[0001] The present invention relates to the field of genetic engineering technology, and in particular to a bovine CRISPR / boCas9 gene editing system, method and application. Background Art
[0002] The CRISPR / Cas9 system is an acquired immune system of bacteria and archaea, consisting of two core components: sgRNA and the Cas9 protein. sgRNA guides the Cas9 protein to a specific target region, while Cas9 acts as a nuclease, capable of cleaving double-stranded DNA. Of all CRISPR / Cas9 systems, the most commonly used is SpCas9, optimized from Streptococcus pyogenes. SpCas9, with its minimalist PAM sequence (5'-NGG-3'), can edit nearly any gene sequence, making it the most widely used gene editing technology.
[0003] Proteins in organisms are composed of 20 amino acids, and there are 64 codons encoding amino acids, with at least one codon corresponding to each amino acid. The frequency of protein codon usage varies greatly among different organisms, with significant biases. Frequently used codons are called optimal codons, while rarely used codons are called rare codons. The closer the codon preference of the coding sequence of an exogenous gene matches that of the target cell, the higher the efficiency of protein translation. Therefore, when using the CRISPR / Cas9 gene editing system in bovine cells, the codon preference of the Cas9 protein derived from Streptococcus pyogenes was optimized to establish a highly efficient bovine-derived CRISPR / Cas9 system for targeting, providing an effective technical means for targeted editing of the bovine genome and modification of biological breeding research.
[0004] Summary of the Invention
[0005] To this end, the present invention provides a bovine CRISPR / boCas9 gene editing system, method and application.
[0006] In order to achieve the above objectives, the embodiments of the present invention provide the following technical solutions:
[0007] According to a first aspect of an embodiment of the present invention, a bovine CRISPR / boCas9 gene editing system is provided, comprising a boCas9 protein and sgRNA; the nucleotide sequence encoding the boCas9 protein is shown in SEQ ID NO.1.
[0008] Furthermore, the sgRNA is selected from any one of sgRNA1-5, wherein,
[0009] The nucleotide sequence of the sense strand of sgRNA1 is shown in SEQ ID NO. 2, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO. 3;
[0010] The nucleotide sequence of the sense strand of sgRNA2 is shown in SEQ ID NO. 4, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO. 5;
[0011] The nucleotide sequence of the sense strand of sgRNA3 is shown in SEQ ID NO.6, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.7;
[0012] The nucleotide sequence of the sense strand of sgRNA4 is shown in SEQ ID NO.8, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.9;
[0013] The nucleotide sequence of the sense strand of sgRNA5 is shown in SEQ ID NO.10, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.11.
[0014] According to a second aspect of the present invention, the present invention utilizes the bovine CRISPR / boCas9 gene editing system as described above to perform a gene editing method, comprising the following steps:
[0015] (1) Construct boCas9 expression vector and sgRNA expression vector respectively;
[0016] (2) co-transfecting the boCas9 expression vector and the sgRNA expression vector into bovine cells;
[0017] (3) Detect the cutting efficiency of the target gene in bovine cells.
[0018] Furthermore, the boCas9 gene sequence was constructed on the pSpCas9 vector to obtain a pboCas9 expression vector.
[0019] Furthermore, the target gene is MSTN, Rosa26, HEBP1, LDLR or PRNP.
[0020] Furthermore, the T7E1 enzyme digestion method was used to detect the cutting efficiency.
[0021] According to a third aspect of the present invention, there is provided the use of the bovine CRISPR / boCas9 gene editing system described above in editing mammalian DNA and transgenic breeding.
[0022] Furthermore, the editing includes genome-targeted excision, insertion or modification.
[0023] The design concept of this invention is as follows: Due to the vigorous development of gene editing technology and molecular breeding, there is an urgent need for a mature gene editing operating system for bovine somatic cells and embryonic cells. Due to codon preference, the gene editing and cutting efficiency of the Cas9 protein derived from Streptococcus pyogenes is low in bovine cells and cannot efficiently complete the cutting of the target gene. Therefore, it is necessary to optimize the bovine cell codon preference of the Cas9 gene derived from Streptococcus pyogenes and establish an efficient bovine-derived CRISPR / boCas9 gene editing system, which is a basic technology for gene knockout, gene insertion and site-directed gene modification.
[0024] The present invention has the following advantages:
[0025] This study established a highly efficient bovine-derived CRISPR / boCas9 gene-editing system. The SpCas9 protein, derived from Streptococcus pyogenes, was codon-optimized for bovine cells. The optimized CRISPR / boCas9 gene-editing system was tested for its cleavage efficiency and compared with the bovine-derived CRISPR / boCas9 gene-editing system at different target sites. The results showed that the bovine-derived CRISPR / boCas9 gene-editing system had a cleavage efficiency at least six times that of the CRISPR / Cas9 gene-editing system, providing an effective technical tool for studying site-specific excision, insertion, and modification of the genome, as well as for transgenic breeding research. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] To more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the embodiments or the description of the prior art. Obviously, the drawings described below are merely exemplary, and those skilled in the art can derive other implementation drawings based on the provided drawings without inventive effort.
[0027] Figure 1 is a flow chart of the method for constructing the CRISPR / boCas9 gene editing system provided by the present invention.
[0028] Figure 2 is a comparison of the cutting efficiency of the CRISPR / boCas9 gene editing system and the CRISPR / SpCas9 gene editing system provided by the present invention for different target genes.
[0029] FIG3 is a comparison of Cas9 protein expression levels in the CRISPR / boCas9 gene editing system and the CRISPR / LwCas9 gene editing system provided by the present invention. DETAILED DESCRIPTION
[0030] The following describes the implementation of the present invention using specific embodiments. Those skilled in the art will readily understand the other advantages and benefits of the present invention from the disclosure herein. Obviously, the embodiments described are only a portion of the present invention, not all of it. All other embodiments derived by persons of ordinary skill in the art based on the embodiments of the present invention without inventive effort are intended to fall within the scope of protection of the present invention.
[0031] In the following examples, the test materials and reagents used include:
[0032] T4 DNA ligase was purchased from Thermo; pSpCas9 was purchased from Addgene; pCMV-sgRNA was purchased from Origene; DMEN medium, Opti-MEM medium, and fetal bovine serum (FBS) were purchased from Gibco; and Lipofectamine 3000 was purchased from Invitrogen.
[0033] In the following examples, molecular biology experimental methods not specifically described were performed according to the specific methods described in the Molecular Cloning Experiment Guide, or according to the kits and product instructions.
[0034] Example 1 Construction of a bovine CRISPR / boCas9 gene editing system
[0035] 1. Based on the known DNA sequence of the SpCas9 protein, predict the DNA sequence in bovine cells, including the following steps:
[0036] (1) The DNA sequence of the SpCas9 gene in bovine cells was optimized using the website https: / / www.novopro.cn / . The optimized boCas9 nucleotide sequence is as follows, where capital letters represent optimized bases:
[0037] (2) The optimized sequence was submitted to BGI for synthesis. After that, the pSpCas9 vector was linearized by BsmBI enzyme digestion. The synthesized optimized sequence was ligated to the linearized vector using T4 DNA ligase and sent to a sequencing company for identification.
[0038] 2. The method for constructing a target gene sgRNA sequence vector includes the following steps:
[0039] (1) Five genes (MSTN, Rosa26, HEBP1, LDLR, and PRNP) were selected as target genes, and their respective sgRNAs were synthesized and cloned into the pCMV-sgRNA vector. The sgRNA sequences of the target genes are as follows:
[0040] The sense strand of sgRNA1 for the MSTN gene is: CAAAGTTGGTGACGTGACAGAGG (SEQ ID NO. 2), and the antisense strand is: CCTCTGTCACGTCACCAACTTTG (SEQ ID NO. 3);
[0041] The sense strand of sgRNA2 for the Rosa26 gene is: GGGACCCGAGCCAATAACAA (SEQ ID NO. 4), and the antisense strand is TTGTTATTGGCTCGGGTCCC (SEQ ID NO. 5);
[0042] The sense strand of sgRNA3 of HEBP1 gene is: TAGGTTCCCATCGTCACT (SEQ ID NO.6), and the antisense strand is: CAGTGACGATGGGAACCTA (SEQ ID NO.7);
[0043] The sense strand of sgRNA4 of the LDLR gene is: GCCATTGTGGTCGATCC (SEQ ID NO. 8), and the antisense strand is: GGATCGACCACAATGGC (SEQ ID NO. 9);
[0044] The sense strand of sgRNA5 of the PRNP gene is: GGAAGCCCTCCTGCCGCAAC (SEQ ID NO.10), and the antisense strand is: GTTGCGGCAGGAGGGCTTCC (SEQ ID NO.11).
[0045] (2) Add AGGAG to the 5'-end and G to the 3'-end of the target gene sgRNA forward oligonucleotide sequence to form a sticky end sequence; add AAAC sequence to the 5'-end and C to the 3'-end of the target gene sgRNA reverse nucleotide sequence; anneal and renature the synthesized forward nucleotide sequence and reverse nucleotide sequence to form a double-stranded oligonucleotide with sticky ends. The procedure is shown in Table 1.
[0046] Table 1 Annealing program
[0047] (3) The pCMV-sgRNA vector was digested with BsmBI restriction enzyme to obtain a linearized vector. The enzyme digestion system is shown in Table 2.
[0048] Table 2 Enzyme digestion system
[0049] The target gene was connected to the linearized vector. The connection system is shown in Table 3.
[0050] Table 3 Connection system
[0051] After ligation at 16°C for 3 h, transformation was performed in DH5α competent cells. Single clones were picked and sent for sequencing to obtain the recombinant expression vector pCMV-sgRNA of the target gene sgRNA oligonucleotide. The correct positive clones were shaken and the plasmid was extracted.
[0052] 3. The optimized pboCas9 expression vector and pCMV-sgRNA expression vector were used to simultaneously transfect bovine muscle satellite stem cells. Positive cells were collected, the cell genome was extracted, and the gene fragment containing the target gene was amplified using its genomic DNA as a template. T7E1 enzyme digestion was performed to identify the knockout of the target gene.
[0053] Example 2 Detection of the Cutting Efficiency of the Bovine CRISPR / boCas9 Gene Editing System
[0054] 1. The bovine CRISPR / boCas9 gene editing system cleavage efficiency test method is T7E1 enzyme cleavage identification, including the following steps:
[0055] (1) Collect some target cells and extract genomic DNA; at the same time, extract genomic DNA from wild-type target cells.
[0056] (2) Amplify the gene fragment containing the target sequence using genomic DNA as a template. The amplification primer sequences are shown in Table 4.
[0057] Table 4 Amplification primer sequences
[0058] (3) T7E1 enzyme was added to the amplified product, and the product was denatured again and subjected to programmed gradient annealing. The program is shown in Table 5.
[0059] Table 5 Denaturation and annealing procedures
[0060] The mutant and wild-type DNA single strands will randomly pair up to form new DNA double strands. The nucleic acid electrophoresis results are evaluated using grayscale analysis software ImageJ. The cutting efficiency f cut The calculation formula is as follows: cut =(the sum of the gray levels of the two bands after enzyme digestion) / (the sum of the gray levels of the three bands in the lane)
[0061] In order to better calculate the cutting efficiency, the cutting efficiency f cut The formula is used to convert the actual mutation rate Indel%, which is:
[0062] Figure 2 compares the cleavage efficiency of the CRISPR / boCas9 and CRISPR / SpCas9 gene editing systems. The left figure (top) shows the T7E1 cleavage activity results for the CRISPR / boCas9 gene editing system, and the left figure (bottom) shows the T7E1 cleavage activity results for the CRISPR / SpCas9 gene editing system. The right figure shows the quantitative statistical graph of the cleavage efficiency of the CRISPR / boCas9 gene editing system (Optimized) and the CRISPR / SpCas9 gene editing system (Mock). Table 6 compares the cleavage efficiency results of the CRISPR / boCas9 and CRISPR / SpCas9 gene editing systems.
[0063] Table 6 Cutting efficiency comparison results
[0064] The results are shown in Table 6 and Figure 2. The cutting efficiency of the optimized CRISPR / boCas9 gene editing system is at least 6 times that of the CRISPR / SpCas9 gene editing system before optimization.
[0065] 2. The expression level of Cas9 protein in the bovine CRISPR / boCas9 gene editing system was determined by Western Blot analysis, which included the following steps: the cultured cells were carefully washed twice with PBS, and 1 mL of protein lysis buffer (990 μL RIPA + 10 μL PMSF), pipetted evenly and placed at 4°C for 30 minutes; centrifuged at 12000 rpm at 4°C for 30 minutes, the supernatant was the protein sample, stored at -80°C, and then subjected to immunoblotting detection. The extracted total protein before and after optimization was used for Cas9 protein immunoblotting detection. Figure 3 is a comparison of the Cas9 protein expression levels of the CRISPR / boCas9 gene editing system and the CRISPR / SpCas9 gene editing system, wherein the upper bands 1-3 in the left figure are the original SpCas9 proteins of the CRISPR / SpCas9 gene editing system before optimization, the upper bands 4-6 in the left figure are the bovine boCas9 proteins of the optimized CRISPR / boCas9 gene editing system, and the lower band GAPDH in the left figure is the internal reference protein; the right figure is a quantitative statistical comparison of the Cas9 protein expression levels of the CRISPR / boCas9 gene editing system (Optimized) and the CRISPR / SpCas9 gene editing system (Mock). The results showed that the protein expression level of the CRISPR / boCas9 gene editing system (Optimized) was twice that of the CRISPR / SpCas9 gene editing system (Mock).
[0066] The research of this invention shows that the optimized CRISPR / boCas9 gene editing system is a gene editing system that efficiently cuts in bovine cells, and can provide an effective technical means for studying genome targeted excision, insertion and modification, as well as for transgenic breeding research.
[0067] Although the present invention has been described in detail above using general descriptions and specific embodiments, it will be apparent to those skilled in the art that modifications and improvements may be made thereto. Therefore, such modifications and improvements, without departing from the spirit of the present invention, are intended to be within the scope of protection claimed herein.
Claims
1. A gene editing method using a bovine CRISPR / boCas9 gene editing system, characterized in that: The steps include: (1) Constructing boCas9 expression vector and sgRNA expression vector respectively; (2) co-transfecting the boCas9 expression vector and the sgRNA expression vector into bovine cells; (3) Detecting the cleavage efficiency of the target gene in bovine cells; The bovine CRISPR / boCas9 gene editing system includes a boCas9 protein and sgRNA; the nucleotide sequence encoding the boCas9 protein is shown in SEQ ID NO.1; The sgRNA is selected from any one of sgRNA1-5, wherein The nucleotide sequence of the sense strand of sgRNA1 is shown in SEQ ID NO.2, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.3; The nucleotide sequence of the sense strand of sgRNA2 is shown in SEQ ID NO.4, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.5; The nucleotide sequence of the sense strand of sgRNA3 is shown in SEQ ID NO.6, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.7; The nucleotide sequence of the sense strand of sgRNA4 is shown in SEQ ID NO.8, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.9; The nucleotide sequence of the sense strand of sgRNA5 is shown in SEQ ID NO.10, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO.
11.
2. The gene editing method according to claim 1, characterized in that The boCas9 gene sequence is constructed on the pSpCas9 vector to obtain a pboCas9 expression vector.
3. The gene editing method according to claim 1, characterized in that The target gene is MSTN, Rosa26, HEBP1, LDLR or PRNP.
4. The gene editing method according to claim 1, characterized in that The cleavage efficiency was detected by T7E1 enzyme digestion method.
5. Use of the bovine CRISPR / boCas9 gene editing system according to claim 1 in editing bovine cell DNA.
6. The use according to claim 5, characterized in that: The editing includes targeted gene excision, insertion or modification.
Citation Information
Patent Citations
Genome editing method
CN108546716A
Safe and efficient CRISPR / Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR associated protein 9) gene editing technology
CN108795902A
Method for knocking down animal mRNA based on CRISPR-Cas13d and application thereof
CN114231561A
Bovine CRISPR / boCas9 gene editing system, methods and applications
CN116286905B
Selective insertion of suicide genes into cancer cells
US20180333505A1
Cited By
Prediction model training method, guiding nucleotide sequence screening method and related device
CN120748487A
Prediction model training method, guide nucleotide sequence screening method, and related device
CN120748487B
